Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles.

[1]  P B Laub,et al.  Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells , 2005, British Journal of Cancer.

[2]  J. Briones,et al.  Role of the STAT1 pathway in apoptosis induced by fludarabine and JAK kinase inhibitors in B-cell chronic lymphocytic leukemia , 2005, Leukemia & lymphoma.

[3]  P. Brown,et al.  Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[4]  R. Scully,et al.  Molecular Functions of BRCA1 in the DNA Damage Response , 2004, Cancer biology & therapy.

[5]  S. Hanks,et al.  Focal Adhesion Kinase Suppresses Apoptosis by Binding to the Death Domain of Receptor-Interacting Protein , 2004, Molecular and Cellular Biology.

[6]  Rolf Larsson,et al.  Multiparametric evaluation of apoptosis: effects of standard cytotoxic agents and the cyanoguanidine CHS 828. , 2004, Molecular cancer therapeutics.

[7]  Yves Pommier,et al.  Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks , 2004, Oncogene.

[8]  M. Blagosklonny.  Prospective strategies to enforce selectively cell death in cancer cells , 2004, Oncogene.

[9]  Bernard Roizman,et al.  STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[10]  C. Beam,et al.  Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. , 2003, Cancer research.

[11]  Nicola Gebbia,et al.  STAT proteins: From normal control of cellular events to tumorigenesis , 2003, Journal of cellular physiology.

[12]  K. Luthman,et al.  Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester): comparison with melphalan , 2003, Anti-cancer drugs.

[13]  A. Veerman,et al.  Cell proliferation is related to in vitro drug resistance in childhood acute leukaemia , 2003, British Journal of Cancer.

[14]  Mitsutoshi Nakamura,et al.  Contributions of mitogen‐activated protein kinase and nuclear factor kappa B to N‐(4‐hydroxyphenyl)retinamide–induced apoptosis in prostate cancer cells , 2002, Molecular carcinogenesis.

[15]  S. Dudoit,et al.  Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. , 2002, Nucleic acids research.

[16]  Yusuke Nakamura,et al.  An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. , 2002, Cancer research.

[17]  D. Geschwind,et al.  An evaluation of tyramide signal amplification and archived fixed and frozen tissue in microarray gene expression analysis. , 2002, Nucleic acids research.

[18]  Qiuping Guo,et al.  A new class of homogeneous nucleic acid probes based on specific displacement hybridization. , 2002, Nucleic acids research.

[19]  J. Marie.  Drug resistance in hematologic malignancies , 2001, Current opinion in oncology.

[20]  J. Mesirov,et al.  Chemosensitivity prediction by transcriptional profiling , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  D. Botstein,et al.  A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.

[22]  T. Hsieh,et al.  Mutations of human topoisomerase IIα affecting multidrug resistance and sensitivity , 1999 .

[23]  G. S. Johnson,et al.  An Information-Intensive Approach to the Molecular Pharmacology of Cancer , 1997, Science.

[24]  K. Nilsson,et al.  Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. , 1996, British Journal of Cancer.

[25]  M. Boyd,et al.  Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen , 1995 .

[26]  K. Nilsson,et al.  Development of vincristine resistance and increased sensitivity to cyclosporin A and verapamil in the human U‐937 lymphoma cell line without overexpression of the 170‐KDa P‐glycoprotein , 1994, International journal of cancer.

[27]  M. Slovak,et al.  Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. , 1993, Cancer research.

[28]  A. Duncan,et al.  Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.

[29]  J N Weinstein,et al.  Neural computing in cancer drug development: predicting mechanism of action. , 1992, Science.

[30]  R. Larsson,et al.  Differential in vitro sensitivity of human tumor and normal cells to chemotherapeutic agents and resistance modulators , 1991, International Journal of Cancer.

[31]  J. Trent,et al.  Development and characterization of a melphalan-resistant human multiple myeloma cell line. , 1991, Cancer research.

[32]  R. Larsson,et al.  Chemotherapeutic drug sensitivity testing of human leukemia cells in vitro using a semiautomated fluorometric assay. , 1990, Leukemia.

[33]  D A Scudiero,et al.  Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. , 1989, Journal of the National Cancer Institute.

[34]  D. Suttle,et al.  Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. , 1988, Biochemistry.

[35]  W. T. Beck,et al.  Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). , 1987, Cancer research.

[36]  D. Alberts,et al.  Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. , 1986, Cancer research.

[37]  L. V. van Putten,et al.  Proliferation-dependent cytotoxicity of anticancer agents: a review. , 1975, Cancer research.

[38]  R. Mulcahy,et al.  Up-regulation of γ-glutamylcysteine synthetase activity in melphalan-resistant human multiple myeloma cells expressing increased glutathione levels , 2004, Cancer Chemotherapy and Pharmacology.

[39]  C. Yu,et al.  Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity. , 1999, Biochemistry.

[40]  S. Mirski,et al.  Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. , 1987, Cancer research.

[41]  PETER ALEXANDER,et al.  Cancer Chemotherapy , 1968, Nature.